12th januari 2025
Het laatste nieuws
Hier vindt u onze laatste persberichten. Blijf op de hoogte van het laatste nieuws en van de evenementen waar Curium aanwezig is.
8th april 2024
Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczacibaşi-Monrol
25th oktober 2023
Curium en PIUR IMAGING kondigen samenwerking aan op het gebied van schildklierbeeldvorming in duitsland om tomografische 3D-echografieoplossingen mogelijk te maken
7th september 2023
Curium announces exclusive distribution agreement in Switzerland with b.e. Imaging for PYLCLARI™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
15th augustus 2023
Curium announces achievement of co-primary endpoints in phase 2 of its phase 1/2 SOLAR clinical trial imaging men with histologically-proven prostate cancer using copper Cu 64 PSMA I&T
28th juli 2023
Curium receives marketing authorization in the EU for Pylclari™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
25th juli 2023
Curium announces license and development agreement with Lantheus for AI-based PSMA PET software in Europe
21st juli 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
21st juli 2023
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
26th mei 2023
Curium receives positive CHMP opinion of PYLCLARI® for primary staging of patients with high-risk PCa prior to initial curative therapy and to localize recurrence of PCa in patients with a suspected recurrence based on increasing serum Prostate-Specific Antigen (PSA) levels after primary treatment with curative intent
23rd mei 2023
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T
2nd mei 2023
Curasight and Curium announce global partnership for uTRACE® in prostate cancer
14th maart 2023
Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial
2nd maart 2023
Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO
21st december 2022
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
24th november 2022
Curium’s Customers to benefit from Mo-99 Production restart
22nd november 2022
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
9th november 2022
Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
18th augustus 2022
NRG and Curium Sign Multi-Year Isotope Production Contract
27th juni 2022